Shengning Pan
Papers
1
Total Citations
39
H-Index
1
About
Shengning Pan is a leading urological surgeon and researcher whose work centers on improving functional outcomes following robot-assisted radical prostatectomy (RARP) for localized prostate cancer. His primary research areas include nerve-sparing surgical techniques, intraoperative pathology guidance, and postoperative quality-of-life preservation. Dr. Pan’s most notable contribution is his leadership in the landmark NeuroSAFE PROOF trial, a multicentre, patient-blinded, randomized phase 3 study published in 2025. This trial demonstrated that NeuroSAFE-guided RARP—a technique using standardized intraoperative frozen section analysis to detect positive margins in real time—significantly improves erectile function and early urinary continence recovery compared to standard RARP. With 39 citations already, this work has rapidly become a cornerstone reference in urologic oncology. By integrating precise pathological feedback into the surgical workflow, Dr. Pan has helped shift the paradigm from purely oncologic outcomes toward a more holistic approach that prioritizes patients’ long-term functional well-being. His research continues to influence surgical protocols and training worldwide, making him a key figure in the advancement of personalized, function-preserving prostate cancer surgery.
Research Focus
Key Achievements
Top Papers
- 1